For many patients with advanced EGFRM+ NSCLC the estimated median OS is reaching three years, thanks to the subsequent or combined employment of EGFR-TKIs and chemotherapy or immunotherapy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.